Pharm 3 SE #2 Flashcards

1
Q

What are some adverse effects/drug interactions of antimuscarinics?

A

Poor absorbtion, Dryness of mouth, urinary symptoms, Bitter metallic taste (ipratropium), nebulization with mask over eyes may precipitate acute glaucoma, Anticholinergic side effects in mod to severe renal function, additive interaction with other anticholinergics.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Prototype SAMA

A

Ipratropium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prototype LAMA

A

Tiotropium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Prototype SABA

A

Albuterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Prototype DPI LABA

A

Salmeterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Prototype Nebulized solution LABA

A

Formoterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Phosphodiesterase inhibitor, therapy must be individualized to achieve optimal responses and minimal side effects.

A

Theophylline - used for the treatment of asthma and COPD for decades. Currently, the role of theophylline is limited for these indications due to the introduction of inhaled bronchodilators and the potential for serious adverse reactions with xanthine derivatives. Theophylline is now considered as last-line or adjunct therapy for these indications. Theophylline has a narrow therapeutic range, and changes in dosing should only occur after a serum concentration is obtained.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

At low doses, this drug can cause nausea, irritability, insomnia, headache, vomiting. At high doses, it can cause ventricular arrhythmias, seizures

A

Theophylline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

This drug should not be given in patients with cirrhosis or patients who smoke cigarettes.

A

Theophylline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the key points of bronchodilators?

A

Inhaled treatment is preferred, Long-acting bronchodilators are preferred, consider combo mechanisms, LAMA has a greater effect on exacerbation rates vs LABA, Theophylline not recommended unless other long-term tx are not an option.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Does regular treatment of ICS improve disease progression or mortality?

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Are ICS as a monotherapy recommended?

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ICS should have the best effect if blood eosinophil count is what?

A

Blood eosinophil count > 300 cells/ul

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the holy trinity of COPD treatment that improves lung function, symptoms and health status and reduces exacerbation.

A

ICS + LABA + LAMA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Do ICS put you at an increased risk of pneumonia?

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What should ICS be used in combination with for COPD?

A

Long-acting bronchodilators

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Name a LABA + ICS combo that is a DPI.

A

Fluticasone/Salmeterol (advair)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Name a LABA +ICS combo that is a MDI

A

Budesonide/Formoterol (symbicort)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Name a ICS + LAMA + LABA combo. DPI

A

Fluticasone, umeclidinium, vilanterol (Trelegy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

This is a phosphodiesterase-4 inhibitor. Adverse effects ae nausea, reduced appetitie, abd pain, diarrhea, sleep disturbances, headache. You must monitor weight loss and depression.

A

Roflumilast (Daliresp)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

PDE-4 inhibitors must always be used in combination with what?

A

One long-acting bronchodilator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

These drugs can be used as anti-inflammatory drugs for COPD.

A

Azithromycin and Erythromycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the adverse effect of azithromycin?

A

Increased bacterial resistance, impaired hearing tests.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the adverse effect of Erythromycin?

A

GI discomfort

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
FEV1: 50-79% predicted
Moderate GOLD 2
26
FEV1: 30-49% predicted
Severe GOLD 3
27
What two vallidated questionnaires do we use to assess COPD?
COPD Assessment Test (CAT) | Modified British Medical Research Council (mMRC)
28
Which test only looks at dyspnea?
mMRC
29
Name the two groups that are mMRC 0-1 or CAT<10.
A and C
30
Name the two groups that are mMRC ≥2 CAT ≥ 10
B and D
31
Treatment for Group A COPD
Bronchodilator
32
Treatment for Group C COPD
LAMA
33
Treatment for Group B COPD
LABA or LAMA
34
Treatment for Group D COPD
LAMA, or LAMA+LABA, or ICS+LABA
35
What two COPD treatment groups are considered if there are 0 or 1 moderate exacerbations not leading to hospitalization?
Group A or B
36
What two COPD treatment groups are considered if there are ≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization.
Group C or D
37
When treating Dyspnea, what is the next step if a LABA or a LAMA is ineffective?
Use both a LABA + LAMA together
38
When treating Dyspnea, what is next step if a LABA + ICS is ineffective?
Use the trio of LABA+LAMA+ICS
39
When treating Dyspnea, what should you do if the LABA+LAMA combo or the Trio is ineffective?
Consider switching inhaler device or molecules. | Investigate and treat other causes of dyspnea.
40
When treating Dyspnea, what should you do if you're using an ICS and the patient has pneumonia?
Consider de-escalation to just a LABA+LAMA combo
41
When treating Dyspnea exacerbations, when would you jump from a LABA or LAMA straight to a LABA +ICS instead of the LABA/LAMA combo?
If their blood eosinophil count is ≥ 300 and 2 moderate exacerbations or 1 hospitalization.
42
What is the most effective anti-inflammatory med class available for asthma?
ICS
43
Response to this drug therapy includes: symptoms improve in 1-2 weeks 4-8 max, FEV1 requires 2 mo for max improvement.
ICS
44
What may be a systemic adverse effect of ICS
Alterations in glucose metabolism.
45
What strategies reduce potential for adverse of events when using ICS?
``` Using a holding chamber Rinse mouth Using lowest dose possible Using in combination with LABAs Avoiding drugs that are CYP3A4 inhibitors like Ritonavir, ketoconazole ```
46
These drugs stimulate adenyl cyclase resulting in increased intracellular cyclic AMP which triggers bronchial smooth muscle relaxation. They selectively work on beta 2 receptors.
LABA
47
For Asthma, are LABA's appropriate as a monotherapy?
No
48
Salmeterol has a box warning of what?
Increased risk of asthma-related death.
49
What ICS LABA combos are there for asthma?
Fluticaslone/Salmeterol (Advair) Fluticasone/Vilanterol (Breo) Budesonide/Formoterol (Symbicort)
50
What are the main adverse effects of Leukotriene RREceptor Antagonist (LTRA)?
Nightmares and neuropsychiatric events.
51
What is the most effective medication for relief of acute bronchospasms?
SABA
52
What SABA uses frequency indicates inadequate asthma control?
using > 2 days/week.
53
These are used in treatment of asthma exacerbations and in treatment of impending episodes of severe asthma unresponsive to bronchodilator therapy.
Oral steroids
54
What are the monitoring intervals for asthma?
2-6 weeks, follow up 1-6 months, step-down therapy in 3 mo intervals.
55
What are 1st line agents for HTN
ACE/ARBS, Ca channel blockers, Thiazide diuretics
56
What are the criteria for diagnosing HTN?
2 or more properly measured BP readings taken 1-2 minutes apart and BP is elevated when measuring two or more visits spaced 1-4 weeks apart.
57
What is the 10-year risk of stroke or MI in an elevated 120-129/<80 BP and what is the recommendation?
N/A 10-year risk | Non-pharm, reassess in 3-6 mo.
58
What is the 10-year risk of a Stage 1 130-139/80-89? What is the recommendation?
<10% 10-year risk Non-pharm, reassess in 3-6 mo If ≥10% or clinical ASCVD then non-pharm +med and reassess in 1 month.
59
What is the 10-year risk and recommendation of a stage 2 ≥140/90?
N/A 10-year risk | Non-pharm + meds (2)
60
JNC8 BP goals for: | General population <60 years, Chronic kidney disease, ≥18 years, and Diabetes, ≥18 years.
<140/90mmHg
61
JNC8 BP goal for General population ≥60 years.
<150/90 mmHg
62
If the patients BP is ≥130/80 mmHg what other guidelines indicates use of meds.
If they also have a clinical CVD, a 10-year ASCVD risk ≥10% or if their BP is ≥140/90 mmHg
63
What are 2nd line HTN meds?
Loop diuretics, Potassium-sparing diuretics, Aldosterone antagonist diuretics, Beta blockers, alpha 1 blockers, Alpha agonist, Vasodilators.
64
For patients with BP >20/10 mmHg over their goal.
You can give two first-line agents of different classes except you can't combine ACE and ARBs.
65
What broad class of drugs should you consider to reduce blood volume (reduces CVP and CO)?
Diuretics
66
What broad class of drugs should you consider if you want to reduce cardiac output (Decrease HR, contractility, and stroke volume)
Beta blockers and Non-dihydropyridine calcium channel blockers.
67
Inhibit sodium chloride cotransporter in distal convoluted tubule in the kidney --> increased sodium and chloride excretion.
Thiazide diuretics
68
SE: hypokalemia*; metabolic alkalosis; hypotension; sun sensitivity; hyperglycemia; hypo-natremia, magnesemia, -phosphatemia; hypercalcemia SSE are: cardiac arrhythmias, SJS
Thiazide diuretics
69
Not appropriate for: patients with active gout; caution with history of gout; anuricpatients; less effective in patients with CrCl <30ml/min
Thiazide Diuretics
70
SE are: cough; hypotension; dizziness; headache; hyperkalemia.
ACE inhibitor
71
Not appropriate for pregnant patients and those with a hx of angioedema.
ACE inhibitors and ARBS
72
SE: Hypotension; dizziness; headache; hyperkalemia. SSE: Angioedema
ARBs
73
Ca channel blockers that are more selective for vascular cells; minimal direct cardiac effects.
Dihydropyridines - Amlodipine, nifedipine, felodipine
74
Ca channel blockers that are more selective for cardiac myocytes; less effects on systemic vasodilation.
Non-dihydropyridines - Diltiazem, verapamil
75
SE are: Hypotension, dizziness, peripheral edema*
Dihydropyridines like amlodipine
76
Effective as antihypertensive as well as anti-arrhthmics.
Non-dihydropyridines
77
Not appropriate for patients with heart failure*, bradycardia*, hypotension
Non-dihydropyridines
78
Side effects: Bronchospasm, bradycardia, hypotension, dizziness, fatigue, depression.
Beta blockers
79
Boxed warning: Abrupt cessation of therapy may lead to angina, myocardial infarction, death.
Beta blockers
80
BB's of choice for heart failure with a reduced ejection fraction.
Metoprolol succinate, carvedilol, and bisoprolol.
81
Inhibit sodium-potassium-chloride cotransporter in the thick ascending limb
Loop diuretics
82
Side effects: hypomagnesemia; hypokalemia; hyperuricemia; hypotension; metabolic alkalosis SSE: Ototoxicity, anemia, thrombocytopenia, SJS.
Loop diuretics
83
inhibit sodium channels in late distal convoluted tubule and collecting ducts. Used to prevent hypokalemia.
Potassium-sparing diuretics - Amiloride and triamterene.
84
SE: gynecomastia and erectile dysfunction.
Aldosterone antagonist diuretics - Spironolactone
85
Block the action of aldosterone at distal segment of the distal tubule; compete for the aldosterone-dependent sodium-potassium exchange site in distal tubule cells --> increased secretion of water and sodium.
Aldosterone antagonist diuretics - Spironolactone
86
Last line treatment for HTN, these act as vasodilators acting in the CNS to reduce sympathetic outflow from the CNS -- > decreased peripheral resistance, renal vascular resistance, heart rate and blood pressure.
Alapha-2 Agonists (clonidine, Methyldopa, Guanfacine)
87
This drug may be considered an add-on for resistant hypertension. Highly specific action on arterial vessels reduces vascular resistance and arterial pressure. Opening of K+ channels to cause smooth muscle hyperpolarization; inhibition of calcium release in smooth muscle; stimulates formation of nitric oxide to produce vasodilation. Has a SSE of lupus-like syndrome.
Hydralazine